Tandem Diabetes Care, Inc. (TNDM) — ESG & Values Scores

Environment story

TNDM operates as a diabetes device manufacturer with minimal direct Scope 1/2 emissions disclosures in filed documents. No net-zero target, carbon reduction commitments, or sustainability reporting framework identified in 10-K. International operations across 25+ countries and global supply chain expose company to resource-intensive manufacturing and logistics. No evidence of substantive decarbonization infrastructure investments, renewable energy transition, or Scope 3 supply-chain emissions measurement. Absence of environmental controversies in 10-K suggests operational compliance but does not indicate proactive ESG leadership. Score reflects baseline compliance posture without verified climate commitments or transparency.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Manufacturing Footprint Expansion

Company operates multiple manufacturing facilities in San Diego, CA, and relies on third-party contract manufacturers in Mexico and Costa Rica. Ongoing expansion of manufacturing capacity to meet demand.
Supply Chain Diversification

Sourcing components from suppliers in China, Mexico, and Costa Rica to support global operations. Subject to tariff and trade policy uncertainties.

Social story

TNDM discloses limited workforce diversity, compensation, and labor relations data. No CEO-to-median-worker pay ratio reported in 10-K; proxy materials would be required for this metric. No documented union-suppression activities or major strikes in past 24 months identified. Leadership diversity percentages not explicitly stated in 10-K; executive team and board composition details absent. No supply-chain labor audits or human-rights due diligence disclosures identified. Company emphasizes clinical support, customer training, and sales infrastructure expansion but does not publicly detail labor practices, diversity targets, or supply-chain ethics programs in filing. Score reflects data gaps and lack of proactive social disclosures rather than identified violations.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Customer Education and Support Infrastructure

Expansion of clinical staff, diabetes educators, and customer support personnel to train new customers on pump use and provide ongoing training specific to products.

Supports accessibility and product adoption among diverse patient populations including type 1 and type 2 diabetes cohorts.
Workforce Expansion for Commercial Growth

Sales force expansion in United States and hiring for direct operations in Europe to support commercial infrastructure.

Job creation in developed markets; no disclosure of diversity or equity targets in hiring.
International Market Operations

Operations in 25+ countries with localized sales, clinical, and support teams. Compliance with local employment and labor laws.

Governance story

TNDM exhibits standard governance infrastructure without evidence of major compliance failures or shareholder activism challenges. No dual-class share structure identified in 10-K; single class of common stock implied. Board independence percentage not disclosed in source documents; proxy statement required for detailed board composition and independence metrics. No active lobbying spend disclosed targeting environmental deregulation or consumer-protection rollbacks. No antitrust, consumer-safety, or financial-fraud proceedings disclosed in 10-K. Litigation settlement of $20.0 million in 2025 related to Roche Cross-License Agreement indicates IP dispute resolution; no indication of consumer-harm or regulatory violation. Company subject to standard FDA/medical-device regulatory oversight and post-market surveillance requirements. Absence of major governance red flags reflects mid-sized biomedical device company compliance posture.

Criticisms on file

Roche Cross-License Agreement Litigation Settlement
Source: TNDM 10-K FY2025, MD&A, Litigation and Settlement Expense section; Item 8 Financial Statements Note 4

Disclosed initiatives

Regulatory Compliance and Post-Market Surveillance

Compliance with FDA 510(k) clearance process, CE marking for EU markets, and post-market adverse-event monitoring. Quality assurance and regulatory affairs teams embedded in operations.

Supports product safety and market access; standard for medical-device industry.
Cybersecurity and Data Protection

Implementation of cybersecurity protections for data infrastructure and compliance with GDPR and E.U. privacy laws in international operations.

Mitigates risk of data breach and regulatory action related to privacy violations.
Convertible Debt Management

Issuance of $316.3 million Convertible Senior Notes due 2029 at 1.50% interest; repayment of 2025 Notes. Capped call transactions to limit dilution.

Manages shareholder dilution and refinancing risk; standard capital structure management.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Tandem Diabetes Care, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Tandem Diabetes Care, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)